Department of Health and Human Services, through National Institutes of Health, awarded Dare Bioscience, Inc. of San Diego, CA $2,000,000 under the SBIR program (Phase II), with work starting 2024-12-17 and running to 2027-11-30. It is the only SBIR or STTR award to Dare Bioscience, Inc. in the last two years. Each figure links to the federal record.
The award
| Recipient | Dare Bioscience, Inc. (San Diego, CA) |
|---|---|
| Awarding agency | Department of Health and Human Services |
| Awarding office | National Institutes of Health |
| Phase | Phase II |
| Amount obligated | $2,000,000 |
| Period of performance starts | 2024-12-17 |
| Period of performance ends | 2027-11-30 |
| Award number | R44AI188623 (grant, CFDA 93.855) |
| Assistance listing | 93.855, Allergy and Infectious Diseases Research |
| Place of performance | San Diego, San Diego County, CA |
| Recipient registry id (UEI) | UC4EFLZHANH4 |
Want the whole picture on Dare Bioscience, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Dare Bioscience, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Dare Bioscience, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
7 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
What it is for
A first-in-class product for the clearance of high-risk human papillomaviruses - summary daré bioscience is developing dare-hpv, an innovative anti-viral vaginal insert to address the health threat posed by persistent hi
Funding actions on this award
| Date | Action | Modification | Amount |
|---|---|---|---|
| 2026-09-14 | Revision | 001 | $0 |
| 2026-05-20 | Continuation | 000 | $1,000,000 |
| 2024-12-17 | New | 000 | $1,000,000 |
A first-in-class product for the clearance of high-risk human papillomaviruses - summary daré bioscience is developing dare-hpv, an innovative anti-viral vaginal insert to address the health threat posed by persistent high-risk human papillomaviruses (hr-hpv) infections, which are associated with cervical cancers. With a lack of fda-approved treatments for persistent hr-hpv infections, this novel therapy combines two antiretroviral drugs, lopinavir and ritonavir, targeting the viral lifecycle and restoring normal cellular growth. A clinical proof-of-concept study showed promising results, with a significant proportion of women experiencing hr-hpv viral clearance 12 weeks after a 14-DAY treatment. The proposed SBIR Phase II studies are focused on achieving three main objectives to ensure dare-hpv’s safety before submitting an ind application. First, they aim to optimize and validate analytical assays for measuring the active pharmaceutical ingredients presence in both blood and cervical samples. Second, they will conduct comprehensive intravaginal safety and toxicity studies in a relevant biological model, female sheep. These studies are designed to confirm the absence of clinical pathology and define the pharmacokinetic parameters in the blood and cervical tissue after administration. Third, they will evaluate the potential for dare-hpv dermal hypersensitivity and evaluate the ...
From the federal award record.
Every other federal award to Dare Bioscience, Inc. on record
The federal register lists 6 other awards to the same registry id (UEI UC4EFLZHANH4), $6,065,761 in all, from 1 agency.
| Starts | Agency | Amount | Award |
|---|---|---|---|
| 2023-08-01 | National Institutes of Health | $907,702 | Therapeutic targeting of FKBP51 for the prevention of stress-induced preterm birth - summary in the united sta (R44HD113465) |
| 2023-08-01 | National Institutes of Health | $384,972 | Therapeutic targeting of FKBP51 for the prevention of stress-induced preterm birth - in the united states, one (R41HD113465) |
| 2022-04-01 | National Institutes of Health | $249,336 | Defining end-user preferences among US women to optimize the design of a long-acting injectable hormonal contr (R43HD108820) |
| 2021-09-21 | National Institutes of Health | $277,996 | Subcutaneous insertion and removal of a user-controlled, long-acting, and reversible contraceptive device - mo (R43HD107685) |
| 2020-08-18 | National Institutes of Health | $2,307,527 | A novel intravaginal ring technology featuring the sustained release of natural progesterone for the preventio (R44HD101169) |
| 2018-05-02 | National Institutes of Health | $1,938,228 | Safety, and acceptability of a non-hormonal vaginal ring (R44HD095724) |
More on Dare Bioscience, Inc.
Dare Bioscience, Inc.'s funding history and team
Who runs it, who owns it, where the money comes from and what to watch for, every claim linked to its source.
Order Full Report on Dare Bioscience, Inc.Look up Dare Bioscience, Inc. and see what is on record before you decide.
Get the free SnapshotWhere this comes from
The Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs set aside part of federal research budgets for small companies. Agencies award them in phases: Phase I tests whether an idea is feasible, Phase II funds development, and Phase III is follow-on work paid for outside the set-aside. STTR awards also require a research institution as a partner.
Every figure on this page is taken from the award's own federal record, linked beside it, as it stood when the page was built: the recipient, its address, the awarding agency and office, the amount obligated so far, the dates and the description. Phase and program are shown as the award's own description states them. The amount can grow later if the agency adds funding to the same award.